Equities

4Basebio PLC

4Basebio PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,300.00
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change+142.99%
  • Beta1.8459
Data delayed at least 20 minutes, as of Nov 21 2024 16:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

4basebio PLC is a United Kingdom-based biotechnology company. The Company is focused on life sciences and in particular the development of synthetic Deoxyribonucleic acid (DNA) and nanoparticles suitable for inclusion in, or delivery of, therapeutic payloads for cell and gene therapies and vaccines. It is engaged in the development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads in patients. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications.

  • Revenue in GBP (TTM)596.00k
  • Net income in GBP-9.84m
  • Incorporated2020
  • Employees--
  • Location
    4Basebio PLC25 Norman Way, OverCAMBRIDGE CB24 5QEUnited KingdomGBR
  • Phone+44 122 396 7943
  • Websitehttps://www.4basebio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Skinbiotherapeutics PLC161.65k-2.88m37.12m11.00--8.47--229.64-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Poolbeg Pharma PLC0.00-4.38m38.00m8.00--3.05-----0.0088-0.00880.000.02490.00----0.00-29.11---30.18--------------0.00------16.11------
Futura Medical PLC8.40m-3.75m101.06m12.00--12.86--12.03-0.0126-0.01260.02720.02590.85385,710.277.20699,850.80-38.14-79.25-47.43-127.2267.70---44.68-914.373.75--0.00-------11.40--219.68--
Scancell Holdings Plc0.00-5.86m139.44m61.00---------0.0068-0.00680.00-0.00380.00----0.00-23.24-31.66-32.48-37.66-------822.37----1.21---100.00--50.91--131.54--
hVIVO PLC64.38m17.45m150.36m274.008.763.917.282.340.02520.02520.09320.05650.9242--4.25234,974.5025.04-0.64346.68-1.29----27.10-0.7651.60--0.2530--15.6135.402,176.68--136.55--
Faron Pharmaceuticals Oy0.00-26.34m153.95m34.00--133.95-----0.3166-0.31660.000.0110.00----0.00-130.90-213.06-443.92-963.12-----------5.990.9022-------7.71---16.05--
Avacta Group Plc22.62m-25.89m163.42m154.00--3.32--7.22-0.0867-0.08670.0750.13340.25554.633.15146,876.60-29.24---61.16--42.08---114.45--1.21-1.230.3875--140.83--32.54------
4Basebio PLC596.00k-9.84m166.54m--------279.43-0.7843-0.78430.0476-0.40750.05080.645310.64---83.78---97.43--69.63---1,650.67--2.53-18.441.51--88.81---48.83------
Bioventix PLC13.61m8.10m195.74m17.0024.5316.3123.8414.391.531.532.572.301.011.572.26800,387.6059.9558.3367.2463.6293.2093.0959.5164.127.07--0.0090.926.177.93-3.296.67-28.4016.25
Allergy Therapeutics plc55.20m-40.22m262.15m635.00--70.83--4.75-0.0107-0.01070.01370.00080.83892.097.40---61.12-22.88-86.97-30.1553.8766.47-72.86-24.881.01-8.700.8931---7.36-5.626.63--1.88--
Puretech Health PLC369.96k-65.19m388.36m90.00--1.56--1,049.74-0.2378-0.23780.00141.040.0007--0.22524,110.65-14.134.92-16.355.94-----19,222.22352.67----0.07280.00-78.68-30.64-30.47---44.10--
Oxford BioMedica plc97.28m-142.02m436.93m834.00--6.56--4.49-1.44-1.440.96420.62920.30124.094.21136,252.10-51.98-19.60-66.85-24.6836.7450.74-172.59-44.382.07-12.470.6077---36.046.04-302.20---0.6307--
Data as of Nov 21 2024. Currency figures normalised to 4Basebio PLC's reporting currency: UK Pound GBX

Institutional shareholders

37.75%Per cent of shares held by top holders
HolderShares% Held
M&G Investment Management Ltd.as of 12 Nov 20244.63m36.12%
Aramea Asset Management AGas of 30 Jun 2022143.33k1.12%
Deutsche Bank AG (Private Banking Germany)as of 30 Sep 202451.67k0.40%
DWS Investment GmbHas of 30 Aug 202413.36k0.10%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.